zurück ECOG 8282


verbessert eine Radiochemotherapie der Ergebnis einer alleinigen Bestrahlung bei inoperablen Pankreaskarzinomen?
Ergebnis (1) Die zusätzliche Chemotherapie erhöht die Toxizität, verbessert aber nicht das Überleben.
- Radio-Chemo nur RT
Response 9% 6%
DFS 5,1 M 5,0 M
Response 8,4 M 7,1 M
Behandlungs-Arm A 59,4 Gy, ED 1,8 Gy, 1000mg/qm 5-FU an Tag 2-5 als Dauerinfusion, 10 mg/qm Mitomycin an Tag 2, q29
Behandlungs-Arm B 59,4 Gy, ED 1,8 Gy
  • 114 Fäll
  • inoperables Pankreaskarzinom


1.) Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG; Eastern Cooperative Oncology Group:
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
IJROBP 62 (2005) 1345-50.

2.) Loehrer PJ, et al.:
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial.
JCO 2011 [Epub ahead of print]

PATIENTS AND METHODSPatients with localiz14.09.2014 10:47gned to receive GEM alone (at 1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks) or GEM (600 mg/m(2)/wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m(2) for 3 of 4 weeks) plus radiotherapy (starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy). Measurement of quality of life using the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire was also performed.ResultsOf 74 patients entered on trial and randomly assigned to receive GEM alone (arm A; n = 37) or GEM plus radiation (arm B; n = 34), patients in arm B had greater incidence of grades 4 and 5 toxicities (41% v 9%), but grades 3 and 4 toxicities combined were similar (77% in A v 79% in B). No statistical differences were seen in quality of life measurements at 6, 15 to 16, and 36 weeks. The primary end point was survival, which was 9.2 months (95% CI, 7.9 to 11.4 months) and 11.1 months (95% CI, 7.6 to 15.5 months) for arms A and B, respectively (one-sided P = .017 by stratified log-rank test). CONCLUSIONThis trial demonstrates improved overall survival with the addition of radiation therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity.

Impressum            Zuletzt geändert am 16.09.2012 21:13